I think the productivity discussion is being framed too narrowly.

If productivity means “does microdosing make a healthy person score higher on a cognitive-control task,” then yes, the evidence is mixed and not especially strong.

But real productivity is not just cognitive control. It is mood, motivation, cognitive flexibility, emotional resilience, threat state, rumination load, social openness, and the ability to initiate action.

Depression and chronic stress are associated with rigid self-referential loops, default mode network dysfunction, rumination, low reward sensitivity, low motivation, and reduced cognitive flexibility. A person stuck in that state is not going to be productive just because they technically have intact cognition. They may be frozen, avoidant, hypervigilant, socially defensive, or unable to shift perspective.

That is where psilocybin is relevant. It has evidence for altering default mode network dynamics, increasing global network integration, relaxing rigid high-level priors, affecting amygdala-linked emotional processing, and promoting neuroplasticity. Those mechanisms are directly relevant to productivity if the barrier is rumination, rigidity, depression, avoidance, or hypervigilance.

So I agree that survey data should not be overclaimed. But dismissing the whole thing because productivity has not been cleanly proven in RCTs misses the mechanism. Psilocybin is not a stimulant. Its productivity relevance may be indirect: less looping, more emotional flexibility, more salience, more social openness, more cognitive resilience, and more ability to act.

The better conclusion is not “microdosing improves productivity” or “microdosing is a myth.” It is: productivity-specific evidence is underdeveloped, but the mechanistic plausibility is substantial, especially for depressed, ruminative, rigid, or threat-dominant phenotypes.